BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 25991396)

  • 1. Concomitant methotrexate and tacrolimus augment the clinical response to abatacept in patients with rheumatoid arthritis with a prior history of biological DMARD use.
    Takahashi N; Fujibayashi T; Kida D; Hirano Y; Kato T; Kato D; Saito K; Kaneko A; Yabe Y; Takagi H; Oguchi T; Miyake H; Watanabe T; Hayashi M; Kanayama Y; Funahashi K; Hanabayashi M; Hirabara S; Asai S; Takemoto T; Terabe K; Asai N; Yoshioka Y; Ishiguro N; Kojima T
    Rheumatol Int; 2015 Oct; 35(10):1707-16. PubMed ID: 25991396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of efficacy and safety of tacrolimus and methotrexate in combination with abatacept in patients with rheumatoid arthritis; a retrospective observational study in the TBC Registry.
    Fujibayashi T; Takahashi N; Kida D; Kaneko A; Hirano Y; Fukaya N; Yabe Y; Oguchi T; Tsuboi S; Miyake H; Takemoto T; Kawasaki M; Ishiguro N; Kojima T
    Mod Rheumatol; 2015; 25(6):825-30. PubMed ID: 25775147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant methotrexate has little effect on clinical outcomes of abatacept in rheumatoid arthritis: a propensity score matching analysis.
    Takahashi N; Kojima T; Kida D; Kaneko A; Hirano Y; Fujibayashi T; Yabe Y; Takagi H; Oguchi T; Hanabayashi M; Kato T; Funahashi K; Hayashi M; Tsuboi S; Kanayama Y; Sobue Y; Asai N; Matsumoto T; Watanabe T; Asai S; Ishiguro N
    Clin Rheumatol; 2019 Sep; 38(9):2451-2459. PubMed ID: 31102087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longterm efficacy and safety of abatacept in patients with rheumatoid arthritis treated in routine clinical practice: effect of concomitant methotrexate after 24 weeks.
    Takahashi N; Kojima T; Kaneko A; Kida D; Hirano Y; Fujibayashi T; Yabe Y; Takagi H; Oguchi T; Miyake H; Kato T; Watanabe T; Hayashi M; Kanayama Y; Funahashi K; Asai S; Yoshioka Y; Takemoto T; Terabe K; Asai N; Ishiguro N
    J Rheumatol; 2015 May; 42(5):786-93. PubMed ID: 25834204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical effectiveness and safety of additional administration of tacrolimus in rheumatoid arthritis patients with an inadequate response to abatacept: A retrospective cohort study.
    Suzuki M; Takahashi N; Kida D; Hirano Y; Kato T; Yabe Y; Oguchi T; Fujibayashi T; Hayashi M; Asai S; Ishiguro N; Kojima T
    Int J Rheum Dis; 2019 Dec; 22(12):2199-2205. PubMed ID: 31647174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained Long-Term Retention Rates of Abatacept in Combination with Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis.
    Sato S; Matsumoto H; Temmoku J; Fujita Y; Matsuoka N; Yashiro-Furuya M; Asano T; Suzuki E; Watanabe H; Kanno T; Migita K
    Medicina (Kaunas); 2021 Aug; 57(9):. PubMed ID: 34577837
    [No Abstract]   [Full Text] [Related]  

  • 7. Risk of serious infection, malignancy, or death in Japanese rheumatoid arthritis patients treated with a combination of abatacept and tacrolimus: a retrospective cohort study.
    Tokunaga K; Matsui K; Oshikawa H; Matsui T; Tohma S
    Clin Rheumatol; 2021 May; 40(5):1811-1817. PubMed ID: 33123921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.
    Wells AF; Westhovens R; Reed DM; Fanti L; Becker JC; Covucci A; Keystone EC
    J Rheumatol; 2011 Nov; 38(11):2362-8. PubMed ID: 21885491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting.
    Alten R; Burkhardt H; Feist E; Krüger K; Rech J; Rubbert-Roth A; Voll RE; Elbez Y; Rauch C
    Arthritis Res Ther; 2018 Jan; 20(1):1. PubMed ID: 29329602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of tacrolimus concomitant with biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    Terabe K; Takahashi N; Asai S; Hirano Y; Kanayama Y; Yabe Y; Oguchi T; Fujibayashi T; Ishikawa H; Hanabayashi M; Hattori Y; Suzuki M; Kishimoto K; Ohashi Y; Imaizumi T; Imagama S; Kojima T
    Mod Rheumatol; 2023 Mar; 33(2):292-301. PubMed ID: 35289372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of adjunct tacrolimus treatment in patients with rheumatoid arthritis with inadequate responses to methotrexate.
    Kitahama M; Nakajima A; Inoue E; Taniguchi A; Momohara S; Yamanaka H
    Mod Rheumatol; 2013 Jul; 23(4):788-93. PubMed ID: 22975732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis.
    Akiyama M; Kaneko Y; Kondo H; Takeuchi T
    Clin Rheumatol; 2016 Nov; 35(11):2829-2834. PubMed ID: 26971256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period.
    Emery P; Burmester GR; Bykerk VP; Combe BG; Furst DE; Barré E; Karyekar CS; Wong DA; Huizinga TW
    Ann Rheum Dis; 2015 Jan; 74(1):19-26. PubMed ID: 25367713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronological changes in baseline disease activity of patients with rheumatoid arthritis who received biologic DMARDs between 2003 and 2012.
    Sato E; Tanaka E; Ochiai M; Shimizu Y; Kobayashi A; Shidara K; Hoshi D; Sugimoto N; Inoue E; Seto Y; Nakajima A; Taniguchi A; Momohara S; Yamanaka H
    Mod Rheumatol; 2015 May; 25(3):350-7. PubMed ID: 25619283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE).
    Smolen JS; Wollenhaupt J; Gomez-Reino JJ; Grassi W; Gaillez C; Poncet C; Le Bars M; Westhovens R
    Arthritis Res Ther; 2015 Jun; 17(1):157. PubMed ID: 26063454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of DAS28-CRP remission in patients with rheumatoid arthritis treated with tacrolimus at 6 months by baseline variables.
    Aramaki T; Kawakami A; Iwamoto N; Fujikawa K; Kawashiri SY; Tamai M; Arima K; Kamachi M; Yamasaki S; Nakamura H; Nakashima M; Mizokami A; Furuyama M; Matsuoka N; Ueki Y; Ida H; Origuchi T; Aoyagi K; Eguchi K
    Mod Rheumatol; 2009; 19(6):652-6. PubMed ID: 19787419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients.
    Migita K; Akeda Y; Akazawa M; Tohma S; Hirano F; Ideguchi H; Kozuru H; Jiuchi Y; Matsumura R; Suematsu E; Miyamura T; Mori S; Fukui T; Izumi Y; Iwanaga N; Tsutani H; Saisyo K; Yamanaka T; Ohshima S; Mori N; Matsumori A; Takahi K; Yoshizawa S; Kawabe Y; Suenaga Y; Ozawa T; Hamada N; Komiya Y; Matsui T; Furukawa H; Oishi K
    Arthritis Res Ther; 2015 Dec; 17():357. PubMed ID: 26653668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice.
    Katayama K; Okubo T; Sato T; Ito H; Fukai R; Baba H
    Mod Rheumatol; 2015 Jan; 25(1):50-5. PubMed ID: 24983407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis.
    Guyot P; Taylor P; Christensen R; Pericleous L; Poncet C; Lebmeier M; Drost P; Bergman G
    Arthritis Res Ther; 2011; 13(6):R204. PubMed ID: 22151924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-center, retrospective analysis of efficacy and safety of tacrolimus as a second-line DMARD in combination therapy and the risk factors contributing to adverse events in 115 patients with rheumatoid arthritis.
    Ogasawara M; Tamura N; Kageyama M; Onuma S; Kusaoi M; Toyama S; Sekiya F; Matsudaira R; Nawata M; Tada K; Matsushita M; Kempe K; Amano H; Morimoto S; Yamaji K; Takasaki Y
    Clin Rheumatol; 2012 Feb; 31(2):251-7. PubMed ID: 21773713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.